1. Home
  2. MYGN vs AHH Comparison

MYGN vs AHH Comparison

Compare MYGN & AHH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Myriad Genetics Inc.

MYGN

Myriad Genetics Inc.

HOLD

Current Price

$7.09

Market Cap

625.5M

Sector

Health Care

ML Signal

HOLD

Logo Armada Hoffler Properties Inc.

AHH

Armada Hoffler Properties Inc.

HOLD

Current Price

$6.46

Market Cap

533.8M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
MYGN
AHH
Founded
1991
1979
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Real Estate
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
625.5M
533.8M
IPO Year
1995
2013

Fundamental Metrics

Financial Performance
Metric
MYGN
AHH
Price
$7.09
$6.46
Analyst Decision
Hold
Buy
Analyst Count
13
4
Target Price
$12.58
$8.13
AVG Volume (30 Days)
1.1M
999.8K
Earning Date
11-03-2025
11-03-2025
Dividend Yield
N/A
12.69%
EPS Growth
N/A
N/A
EPS
N/A
0.19
Revenue
$825,300,000.00
$452,636,000.00
Revenue This Year
$0.10
N/A
Revenue Next Year
$5.28
$4.68
P/E Ratio
N/A
$34.21
Revenue Growth
0.21
N/A
52 Week Low
$3.76
$6.01
52 Week High
$16.63
$11.07

Technical Indicators

Market Signals
Indicator
MYGN
AHH
Relative Strength Index (RSI) 47.96 50.64
Support Level $6.93 $6.01
Resistance Level $7.38 $6.67
Average True Range (ATR) 0.39 0.16
MACD 0.03 0.05
Stochastic Oscillator 39.88 69.17

Price Performance

Historical Comparison
MYGN
AHH

About MYGN Myriad Genetics Inc.

Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.

About AHH Armada Hoffler Properties Inc.

Armada Hoffler Properties Inc is a real estate company. It engages in developing, building, owning and managing the high-quality, institutional-grade office, retail, and multifamily properties in various markets throughout the Mid-Atlantic and Southeastern United States. It lease its properties under operating leases and recognize base rents. It also recognize revenue from tenant recoveries, through which tenants reimburses the company for expenses paid by them such as utilities, janitorial, repairs and maintenance. The company's operating segment includes office real estate, retail real estate, multifamily residential real estate, and general contracting, real estate financing and real estate services. It generates maximum revenue from the retail real estate segment.

Share on Social Networks: